Featured Image
Why is it important?
This Phase 1 study confirmed the safety of spartalizumab given at a dose of up to 10 mg/kg every 2 weeks in Japanese patients with cancers.
Read the Original
This page is a summary of: Phase I study of the antiprogrammed cell death‐1 Ab spartalizumab (PDR001) in Japanese patients with advanced malignancies, Cancer Science, December 2020, Wiley,
DOI: 10.1111/cas.14678.
You can read the full text:
Contributors
The following have contributed to this page
